Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
01 sept. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences...
Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
29 août 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at...
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
21 août 2023 07h00 HE
|
Amicus Therapeutics, Inc.
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
15 août 2023 07h00 HE
|
Amicus Therapeutics, Inc.
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for Health and Care Excellence (NICE) Issues...
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
08 août 2023 07h00 HE
|
Amicus Therapeutics, Inc.
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda® Underway; U.S. and U.K. Approvals Expected 3Q...
Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023
31 juil. 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, July 31, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 8, 2023, at...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
27 juin 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for...
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
10 mai 2023 07h00 HE
|
Amicus Therapeutics, Inc.
1Q23 Revenue Growth of 14% at CER to $86.3M On Track to Deliver Full-Year 2023 Galafold Revenue Growth of 12%-17% at CER U.S. FDA Pre-approval Inspection...
Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference
02 mai 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2023 Health Care...
Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023
01 mai 2023 07h00 HE
|
Amicus Therapeutics, Inc.
PHILADELPHIA, May 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, May 10, 2023, at...